News Latest Sep 25, 2025 Theratechnologies Announces Completion of Acquisition by Future Pak Press Releases Year None20252024 Feb 14, 2025 Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update Feb 13, 2025 Theratechnologies Resumes Distribution of EGRIFTA SV® Jan 09, 2025 Theratechnologies Provides Update on EGRIFTA SV® Supply Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Dec 10, 2024 Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 09, 2024 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer Dec 04, 2024 Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada Dec 03, 2024 Theratechnologies Announces Resumed Production of EGRIFTA SV® Dec 02, 2024 Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec Nov 26, 2024 Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 21 - 30 of 61
Feb 14, 2025 Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Dec 10, 2024 Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
Dec 09, 2024 Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
Dec 04, 2024 Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Dec 02, 2024 Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
